371 related articles for article (PubMed ID: 36614045)
21. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
Park W; Wei S; Xie CL; Han JH; Kim BS; Kim B; Jin JS; Yang ES; Cho MK; Ryu D; Yang HX; Bae SJ; Ha KT
Exp Mol Med; 2024 May; 56(5):1137-1149. PubMed ID: 38689087
[TBL] [Abstract][Full Text] [Related]
22. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
23. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M,
Chang Y; Liu S; Jiang Y; Hua L; Wen L
Respir Med Case Rep; 2022; 36():101582. PubMed ID: 35106279
[TBL] [Abstract][Full Text] [Related]
24. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R
Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722
[TBL] [Abstract][Full Text] [Related]
25. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
[TBL] [Abstract][Full Text] [Related]
26. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
[TBL] [Abstract][Full Text] [Related]
27. Two case reports of non-small cell lung cancer patients harboring acquired
Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation.
Jeon J; Jang SY; Kwak EJ; Lee SH; Byun JY; Kim YY; Ahn YG; Singh P; Moon K; Kim IS
Eur J Med Chem; 2023 Dec; 261():115840. PubMed ID: 37783102
[TBL] [Abstract][Full Text] [Related]
29. Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
Yamaguchi O; Kasahara N; Soda H; Imai H; Naruse I; Yamaguchi H; Itai M; Taguchi K; Uchida M; Sunaga N; Maeno T; Minato K; Tomono H; Ogawara D; Mukae H; Miura Y; Shiono A; Mouri A; Kagamu H; Kaira K
Sci Rep; 2023 Nov; 13(1):20848. PubMed ID: 38012343
[TBL] [Abstract][Full Text] [Related]
30. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
Nagasaka M; Balmanoukian AS; Madison R; Zhang SS; Klempner SJ; Ou SI
Lung Cancer; 2022 Feb; 164():52-55. PubMed ID: 35032819
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFR
Guo Y; Gao B; Gao P; Wang Y; Gou S
Bioorg Med Chem; 2023 Jul; 90():117338. PubMed ID: 37269687
[TBL] [Abstract][Full Text] [Related]
32. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
33. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.
Duggirala KB; Lee Y; Lee K
Biomol Ther (Seoul); 2022 Jan; 30(1):19-27. PubMed ID: 34074804
[TBL] [Abstract][Full Text] [Related]
34. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
Arulananda S; Do H; Musafer A; Mitchell P; Dobrovic A; John T
J Thorac Oncol; 2017 Nov; 12(11):1728-1732. PubMed ID: 28843359
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
[TBL] [Abstract][Full Text] [Related]
36. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
37. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
38. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
[TBL] [Abstract][Full Text] [Related]
39. Modification of osimertinib to discover new potent EGFR
Xi XX; Zhao HY; Mao YZ; Xin M; Zhang SQ
Eur J Med Chem; 2023 Dec; 261():115865. PubMed ID: 37839342
[TBL] [Abstract][Full Text] [Related]
40. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring
Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
